Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

931656

	registered interest
	date	26/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Aortic Aneurysm
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they have conducted an impact assessment of the draft NICE Guidelines on Abdominal Aortic Aneurysm, including the impact (1) on patients over 65 years old who may be medically unsuitable for open surgical repair, and (2) of removing certain treatment options when clinical professionals have indicated that patients require such treatment.
	tabling member printed	Baroness Walmsley
	uin	HL9003
	answer	answer is ministerial correction date of answer 09/07/2018 answer text <p>We have made no such assessments. The National Institute for Health and Care Excellence (NICE) is an independent body and has not yet published final guidance on the diagnosis and management of abdominal aortic aneurysm. NICE has recently consulted on its draft guideline and will take the comments it has received in response to the consultation fully into account in finalising its recommendations.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL9004 question first answered 09/07/2018 14:31:56 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	2547 label Biography information for Baroness Walmsley

931658

	registered interest
	date	26/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Aortic Aneurysm
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the availability to UK patients of fenestrated endografts, developed in the UK, manufactured in Scotland and used around the world, if the current draft NICE guidelines on Abdominal Aortic Aneurysm are implemented.
	tabling member printed	Baroness Walmsley
	uin	HL9004
	answer	answer is ministerial correction date of answer 09/07/2018 answer text <p>We have made no such assessments. The National Institute for Health and Care Excellence (NICE) is an independent body and has not yet published final guidance on the diagnosis and management of abdominal aortic aneurysm. NICE has recently consulted on its draft guideline and will take the comments it has received in response to the consultation fully into account in finalising its recommendations.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL9003 question first answered 09/07/2018 14:31:56 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	2547 label Biography information for Baroness Walmsley

931632

	registered interest
	date	26/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Liothyronine
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what action they propose to ensure that the Brighton and Sussex University Hospitals NHS Trust withdraws its policy of no longer making Liothyronine (T3) available to NHS patients, contrary to advice issued by NHS England which sets out the circumstances under which Liothyronine (T3) can be prescribed to new patients and continued for existing patients.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL8980
	answer	answer is ministerial correction date of answer 10/07/2018 answer text <p>The national guidelines advise clinical commissioning groups (CCGs) that local decisions should be made regarding arrangements for the on-going prescribing of liothyronine, taking into account the local needs of the population. While CCGs are expected to have regard to national guidance, they are entitled to develop their own local approaches to its implementation. During a debate on 20 June on the Branded Health Service Medicines (Costs) Regulations, I committed to pursuing further with NHS England ways in which they can clarify the guidelines on the prescribing of liothyronine to CCGs, including looking at whether greater clarity on the criteria for appropriate patient usage is merited.</p><p>The prescribing of Liothyronine (T3) was considered by the Sussex and East Surrey Sustainability and Transformation Partnership (STP) clinical board, which covers Brighton and Sussex University Hospitals, and High Weald, Lewes and Havens CCG, following engagement with primary care clinicians and endocrinologists. Based on the evidence presented, the decision not to routinely prescribe Liothyronine (T3) was supported across the STP region. It was, however, recognised that there would be some exceptions to this and that the use of the individual funding request triage process would be an appropriate mechanism to consider these.</p><p><strong> </strong></p> answering member printed Lord O'Shaughnessy grouped question UIN HL8981 HL8982 HL8983 question first answered 10/07/2018 15:41:18 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

931634

	registered interest
	date	26/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Liothyronine
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the Brighton and Sussex University Hospitals NHS Trust mistakenly stating that the only option for patients wishing to continue Liothyronine (T3) therapy is through the private sector, contrary to advice issued by NHS England which sets out the circumstances under which Liothyronine (T3) can be prescribed to new patients and continued for existing patients.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL8982
	answer	answer is ministerial correction date of answer 10/07/2018 answer text <p>The national guidelines advise clinical commissioning groups (CCGs) that local decisions should be made regarding arrangements for the on-going prescribing of liothyronine, taking into account the local needs of the population. While CCGs are expected to have regard to national guidance, they are entitled to develop their own local approaches to its implementation. During a debate on 20 June on the Branded Health Service Medicines (Costs) Regulations, I committed to pursuing further with NHS England ways in which they can clarify the guidelines on the prescribing of liothyronine to CCGs, including looking at whether greater clarity on the criteria for appropriate patient usage is merited.</p><p>The prescribing of Liothyronine (T3) was considered by the Sussex and East Surrey Sustainability and Transformation Partnership (STP) clinical board, which covers Brighton and Sussex University Hospitals, and High Weald, Lewes and Havens CCG, following engagement with primary care clinicians and endocrinologists. Based on the evidence presented, the decision not to routinely prescribe Liothyronine (T3) was supported across the STP region. It was, however, recognised that there would be some exceptions to this and that the use of the individual funding request triage process would be an appropriate mechanism to consider these.</p><p><strong> </strong></p> answering member printed Lord O'Shaughnessy grouped question UIN HL8980 HL8981 HL8983 question first answered 10/07/2018 15:41:18 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

930914

	registered interest
	date	25/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs: Misuse
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the extent to which the commissioning guidance for the NHS and local government on how to respond to the needs of people who are addicted to prescription and over the counter medicines, published by Public Health England in June 2013, has been implemented.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL8914
	answer	answer is ministerial correction date of answer 09/07/2018 answer text <p>No assessment has been made of the extent to which the commissioning guidance has been implemented. Responding to the needs of people who are addicted to prescription and over the counter medicines is the responsibility of local authorities and the National Health Service in each area. Local authority and clinical commissioning group commissioners should work together to ensure that there are appropriate services and interventions available to meet the needs of their local populations.</p><p>Public Health England supports local commissioners to better understand and address local need, by publishing guidance and supplying information about people in touch with specialist substance misuse services who are being treated for addiction to medicines.</p><p>People who have developed problems with prescription and over the counter medicines should seek help from their general practitioner (GP) in the first instance. Specialist advice for GPs and support for patients with complex and severe problems is available from substance misuse services in each local authority across the country.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL8915 question first answered 09/07/2018 14:18:52 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

930915

	registered interest
	date	25/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs: Misuse
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the extent to which support is available in every area for people with a dependency on prescription or over the counter medicines as set out in the guidance published by Public Health England in June 2013.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL8915
	answer	answer is ministerial correction date of answer 09/07/2018 answer text <p>No assessment has been made of the extent to which the commissioning guidance has been implemented. Responding to the needs of people who are addicted to prescription and over the counter medicines is the responsibility of local authorities and the National Health Service in each area. Local authority and clinical commissioning group commissioners should work together to ensure that there are appropriate services and interventions available to meet the needs of their local populations.</p><p>Public Health England supports local commissioners to better understand and address local need, by publishing guidance and supplying information about people in touch with specialist substance misuse services who are being treated for addiction to medicines.</p><p>People who have developed problems with prescription and over the counter medicines should seek help from their general practitioner (GP) in the first instance. Specialist advice for GPs and support for patients with complex and severe problems is available from substance misuse services in each local authority across the country.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL8914 question first answered 09/07/2018 14:18:52 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

930912

	registered interest
	date	25/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescription Drugs: Misuse
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they will ensure the timely publication of the agenda, papers and minutes of the Public Health England Expert Group on Prescribed Drug Dependence.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL8912
	answer	answer is ministerial correction date of answer 09/07/2018 answer text <p>Public Health England (PHE) has been commissioned to undertake a public health evidence review of available data and published evidence on the problems associated with dependence, and the short term discontinuation or longer term withdrawal symptoms, associated with prescribed medicines.</p><p> </p><p>PHE is aware of the importance and relevance of the experience of patients in understanding the issues. The review will include a call for papers which specifically identifies published accounts of the patients’ experiences, and this material will be specifically and deliberately focused on in the review. This process is distinct from a public inquiry, which would include individual testimony.</p><p> </p><p>PHE is committed to publishing the agenda, papers and minutes of meetings of the expert reference group and the first set of these documents will be available during July 2018.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL8913 question first answered 09/07/2018 14:17:45 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

930913

	registered interest
	date	25/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescription Drugs: Misuse
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether the Public Health England Expert Group on Prescribed Drug Dependence will accept as evidence the individual testimonies of patients.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL8913
	answer	answer is ministerial correction date of answer 09/07/2018 answer text <p>Public Health England (PHE) has been commissioned to undertake a public health evidence review of available data and published evidence on the problems associated with dependence, and the short term discontinuation or longer term withdrawal symptoms, associated with prescribed medicines.</p><p> </p><p>PHE is aware of the importance and relevance of the experience of patients in understanding the issues. The review will include a call for papers which specifically identifies published accounts of the patients’ experiences, and this material will be specifically and deliberately focused on in the review. This process is distinct from a public inquiry, which would include individual testimony.</p><p> </p><p>PHE is committed to publishing the agenda, papers and minutes of meetings of the expert reference group and the first set of these documents will be available during July 2018.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL8912 question first answered 09/07/2018 14:17:45 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

928881

	registered interest
	date	21/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Contraceptives
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they plan to make oral contraceptives available over the counter in pharmacies on the same basis as emergency contraception; and if so, when.
	tabling member printed	Baroness Tonge
	uin	HL8882
	answer	answer is ministerial correction date of answer 04/07/2018 answer text <p>The Government has no specific plans to make oral contraceptive pills available without a prescription. Any applications to reclassify particular products from prescription only to non-prescription supply would need to be initiated by the manufacturer and would then be considered in accordance with its usual procedures by the Medicines and Healthcare products Regulatory Agency.</p><p>In accordance with its usual procedures the Medicines and Healthcare products Regulatory Agency approved an application from Pfizer to reclassify the product Viagra Connect (sildenafil 50mg) from a prescription only medicine to a pharmacy medicine. After full assessment of the available evidence and having sought advice from the Commission on Human Medicines, the product was considered safe to be supplied from pharmacies without prescription.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL8883 question first answered 04/07/2018 16:32:15 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	200 label Biography information for Baroness Tonge

928882

	registered interest
	date	21/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Sildenafil
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government why Viagra has been made available over the counter in pharmacies.
	tabling member printed	Baroness Tonge
	uin	HL8883
	answer	answer is ministerial correction date of answer 04/07/2018 answer text <p>The Government has no specific plans to make oral contraceptive pills available without a prescription. Any applications to reclassify particular products from prescription only to non-prescription supply would need to be initiated by the manufacturer and would then be considered in accordance with its usual procedures by the Medicines and Healthcare products Regulatory Agency.</p><p>In accordance with its usual procedures the Medicines and Healthcare products Regulatory Agency approved an application from Pfizer to reclassify the product Viagra Connect (sildenafil 50mg) from a prescription only medicine to a pharmacy medicine. After full assessment of the available evidence and having sought advice from the Commission on Human Medicines, the product was considered safe to be supplied from pharmacies without prescription.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL8882 question first answered 04/07/2018 16:32:15 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	200 label Biography information for Baroness Tonge